Author details

Full Name

Christine M Hunt

Affiliation

Duke University Medical Center and Durham Veterans Affairs Health Care System

ORCID

Career Start Year

1990

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36191725	Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.	Am J Kidney Dis	2023
37094663	One ALT Is Not Like the Other.	Gastroenterology	2023
36547811	Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration.	Drug Saf	2023
34663578	Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort.	Gut	2022
35349635	Hepatitis B Virus-related Care Quality in Patients With Hepatitis B/Human Immunodeficiency Virus Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study.	Clin Infect Dis	2022
35768681	Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans.	J Gen Intern Med	2022
35684976	Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19.	Clin Transl Sci	2022
35966642	Associations Between Gastrointestinal Symptoms and COVID-19 Severity Outcomes Based on a Propensity Score-Weighted Analysis of a Nationwide Cohort.	Gastro Hep Adv	2022
34444232	COVID-19-Associated Mortality in US Veterans with and without SARS-CoV-2 Infection.	Int J Environ Res Public Health	2021
31697169	Alanine Aminotransferase Results Differ by Analyzer Manufacturer in a National Integrated Health Setting, 2012-2017.	Arch Pathol Lab Med	2020
30766414	Identifying and Treating Nonalcoholic Fatty Liver Disease.	Fed Pract	2019
30867626	Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?	Fed Pract	2019
29115682	Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.	Aliment Pharmacol Ther	2018
30043282	Correction to: Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.	Dig Dis Sci	2018
30202826	Preventing Hepatitis B Reactivation During Anti-CD20 Antibody Treatment in the Veterans Health Administration.	Hepatol Commun	2018
29779083	Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.	Dig Dis Sci	2018
29575769	Expanding our toolkit to better identify drug-induced liver injury in electronic medical records.	Liver Int	2018
29574875	Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH. Authors' reply.	Aliment Pharmacol Ther	2018
29407200	Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury.	Regul Toxicol Pharmacol	2018
28295448	Drug rechallenge following drug-induced liver injury.	Hepatology	2017
27025923	Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.	Regul Toxicol Pharmacol	2016
27753578	Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013.	Mil Med	2016
27217704	Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.	World J Gastroenterol	2016
25988394	Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBaseâ¿¢.	Regul Toxicol Pharmacol	2015
26190302	Children's liver chemistries vary with age and gender and require customized pediatric reference ranges.	Regul Toxicol Pharmacol	2015
24920207	An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data.	Pharmacoepidemiol Drug Saf	2014
25236535	Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database.	Regul Toxicol Pharmacol	2014
23300062	A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.	Pharmacoepidemiol Drug Saf	2013
23556451	Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.	Pharmacogenomics	2013
23258383	Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data.	Pharmacoepidemiol Drug Saf	2013
22057095	Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease.	Regul Toxicol Pharmacol	2012
22928730	Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.	Drug Saf	2012
22668747	A pre-marketing ALT signal predicts post-marketing liver safety.	Regul Toxicol Pharmacol	2012
22357454	Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.	Clin Pharmacol Ther	2012
21544079	Case definition and phenotype standardization in drug-induced liver injury.	Clin Pharmacol Ther	2011
20486732	Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.	Drug Saf	2010
21105110	Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review.	Hepatology	2010
20932869	The evaluation of drug rechallenge: the casopitant Phase III program.	Regul Toxicol Pharmacol	2010
19303041	Drug-induced liver injury following positive drug rechallenge.	Regul Toxicol Pharmacol	2009
19362607	Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.	Clin Gastroenterol Hepatol	2009
19102721	Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1.	Pharmacogenomics	2009
18585425	Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease.	Regul Toxicol Pharmacol	2008
17655994	Monitoring liver safety in drug development: the GSK experience.	Regul Toxicol Pharmacol	2007
11280555	Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.	Am J Gastroenterol	2001
10796877	Clinical relevance of hepatitis B viral mutations.	Hepatology	2000
10493286	Evaluation of a workplace hemochromatosis screening program.	Am J Prev Med	1999
10235207	Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria.	Am J Gastroenterol	1999
10068707	Liver disease in pregnancy.	Am Fam Physician	1999
10549375	Lamivudine therapy of chronic hepatitis B.	Adv Exp Med Biol	1999
9575396	Effect of postoperative complications on health and employment following liver transplantation.	Clin Transplant	1998

1 - 50 of 68

Thoetchai Peeraphatdit

University of Nebraska Medical Center

Career Start Year 2014

Number of shared co-authors 0

Anouar Teriaky

Western University

Career Start Year 2011

Number of shared co-authors 0

Neil Rajoriya

Queen Elizabeth Hospital Birmingham

Career Start Year 2009

Number of shared co-authors 0

Joseph J Larson

Division of Clinical Trials and Biostatistics, Mayo Clinic

Career Start Year 2009

Number of shared co-authors 0

Christopher Koh

Clinical Research Section

Career Start Year 2008

Number of shared co-authors 0

Saleh A Alqahtani

King Faisal Specialist Hospital & Research Centre

Career Start Year 2007

Number of shared co-authors 0

Mayur Brahmania

Cumming School of Medicine

Career Start Year 2004

Number of shared co-authors 0

Gopinath M Subramanian

John Hunter Children's Hospital

Career Start Year 2002

Number of shared co-authors 0

Vincent Lo Re

IRCCS-ISMETT

Career Start Year 2001

Number of shared co-authors 3

Gideon M Hirschfield

University of Toronto

Career Start Year 2001

Number of shared co-authors 0

Byung Seok Kim

Catholic University of Daegu School of Medicine

Career Start Year 2001

Number of shared co-authors 0

Won Young Tak

Kyungpook National University

Career Start Year 2001

Number of shared co-authors 0

Richard Gilroy

Intermountain Medical Center

Career Start Year 2000

Number of shared co-authors 0

Curtis K Argo

University of Virginia

Career Start Year 2000

Number of shared co-authors 0

Ali Zarrinpar

College of Medicine, University of Florida

Career Start Year 1999

Number of shared co-authors 0

Jayant A Talwalkar

Mayo Clinic

Career Start Year 1999

Number of shared co-authors 1

Konstantinos N Lazaridis

Mayo Clinic

Career Start Year 1997

Number of shared co-authors 0

Michael P Curry

Beth Israel Deaconess Medical Center, Harvard Medical School

Career Start Year 1997

Number of shared co-authors 0

Steven-Huy B Han

David Geffen School of Medicine , University of California los angeles

Career Start Year 1997

Number of shared co-authors 1

Fedja A Rochling

University of Nebraska Medical Center

Career Start Year 1997

Number of shared co-authors 0

Theo Heller

National Institute of Diabetes and Digestive and Kidney Diseases

Career Start Year 1996

Number of shared co-authors 0

Peter St??rkel

Cliniques Universitaires Saint-Luc (CUSL)

Career Start Year 1996

Number of shared co-authors 0

Jong Young Choi

Ajou University School of Medicine

Career Start Year 1994

Number of shared co-authors 2

Raymond T Chung

Massachusetts General Hospital and Harvard Medical School

Career Start Year 1992

Number of shared co-authors 1

Nghia H Nguyen

University of California

Career Start Year 1990

Number of shared co-authors 0

Arun J Sanyal

Virginia Commonwealth University

Career Start Year 1989

Number of shared co-authors 4

Peter Richardson

Section of Health Services Research, Baylor College of Medicine

Career Start Year 1989

Number of shared co-authors 2

Terry M Therneau

Mayo Clinic

Career Start Year 1986

Number of shared co-authors 0

Stephen A Harrison

Pinnacle Clinical Research Center

Career Start Year 1983

Number of shared co-authors 0

Paul J Pockros

Scripps Clinic and Scripps Translational Science Institute

Career Start Year 1982

Number of shared co-authors 0

row(s) 1 - 30 of 30

Mary Kay Washington

Co-authored papers 4

Shailja C Shah

University of California San Diego, Veterans Affairs San Diego Healthcare System

Co-authored papers 3

Barbara Phillips-Bute

Duke University Medical Center

Co-authored papers 3

Sony Tuteja

University of Pennsylvania Perelman School of Medicine

Co-authored papers 2

Paul B Watkins

UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill

Co-authored papers 2

Robert A Greevy

Vanderbilt University Medical Center

Co-authored papers 2

Grace L Su

University of Washington

Co-authored papers 2

Richard L Hauger

VA San Diego Healthcare System (VASDHS)

Co-authored papers 2

Kyong-Mi Chang

Corporal Michael J Crescenz VA Medical Center

Co-authored papers 2

Alese E Halvorson

Vanderbilt University Medical Center

Co-authored papers 2

Christianne L Roumie

Vanderbilt University Medical Center

Co-authored papers 2

Michael Matheny

American College of Medical Informatics, Department of Veteran Affairs, Harvard University T H Chan School of Public Health, Massachusetts Institute of Technology, The American Society for Clinical Investigation, University of Kentucky, Vanderbilt University Medical Center, Vanderbilt University Medical School

Co-authored papers 2

Edward D Siew

Vanderbilt O'Brien Center for Kidney Disease, Vanderbilt University Medical Center

Co-authored papers 2

Adriana M Hung

Nashville VA Medical Center, VA Tennessee Valley Healthcare System

Co-authored papers 1

Michael Icardi

University of Iowa

Co-authored papers 1

Andrew Canakis

University of Maryland School of Medicine